Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Crizotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET known ✓ | P08581 | 11/20 | 0.98 |
| ▸ | ALK known ✓ | Q9UM73 | 7/20 | 0.98 |
| ▸ | ROS1 known ✓ | P08922 | 2/20 | 0.98 |
| ▸ | MST1R known ✓ | Q04912 | 2/20 | 0.98 |
| ▸ | NPM1 known ✓ | P06748 | 1/20 | 0.98 |
| ▸ | EML4 known ✓ | Q9HC35 | 1/20 | 0.98 |
| ▸ | JAK2 | O60674 | 7/20 | 0.98 |
| ▸ | MAP4K3 | Q8IVH8 | 7/20 | 0.98 |
| ▸ | JAK3 | P52333 | 4/20 | 0.98 |
| ▸ | JAK1 | P23458 | 3/20 | 0.98 |
| ▸ | TYK2 | P29597 | 3/20 | 0.98 |
| ▸ | PLK4 | O00444 | 2/20 | 0.98 |
| ▸ | AURKA | O14965 | 2/20 | 0.98 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.98 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.98 |
| ▸ | ABL1 | P00519 | 2/20 | 0.98 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.98 |
| ▸ | INSR | P06213 | 2/20 | 0.98 |
| ▸ | LCK | P06239 | 2/20 | 0.98 |
| ▸ | FES | P07332 | 2/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Crizotinib SCHEMBL94020 | 0.99 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL29351506 | 0.99 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL30129754 | 0.99 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL14811801 | 0.99 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL28844302 | 0.99 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL28844303 | 0.99 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL29831970 | 0.99 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL29622387 | 0.99 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL93829 | 0.99 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL1827232 | 0.95 | MET (0.91) | METALKJAK2MAP4K3JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| WO-2024102187-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | PINETREE THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| CN-115872976-B | Quinoline derivative, pharmaceutical composition containing quinoline derivative and application of pharmaceutical composition | 中国药科大学 | 2024-05-14 | — | — | CN | disclosed |
| CN-109890420-B | Platelet compositions and methods for delivering therapeutic agents | 北卡罗来纳州立大学 | 2024-04-09 | — | — | CN | disclosed |
| CN-117337193-A | combination therapy | 基因泰克公司 | 2024-01-02 | — | — | CN | disclosed |
| US-20230302144-A1 | Porphyrin Compounds and Compositions Useful for Treating Cancer | ONCOSELECT THERAPEUTICS, LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-11590233-B2 | Porphyrin compounds and compositions useful for treating cancer | ONCOSELECT THERAPEUTICS, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| CN-109922834-B | Porphyrin compounds and compositions for the treatment of cancer | 良药治疗公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-111007158-B | Method for separating and measuring related substances in preparation process of crizotinib | 上海柏狮生物科技有限公司 | 2022-08-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230302144-A1 | Porphyrin Compounds and Compositions Useful for Treating Cancer | KIT, HCCS, PPIF | MET 643/4885ALK 3057/4885ROS1 1770/4885 |
| US-11590233-B2 | Porphyrin compounds and compositions useful for treating cancer | KIT, HCCS, PPIF | MET 643/4885ALK 3057/4885ROS1 1770/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | MET 4155/4885ALK 4644/4885ROS1 3276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.